Skip to main
AGIO

Agios Pharmaceuticals (AGIO) Stock Forecast & Price Target

Agios Pharmaceuticals (AGIO) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 13%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Agios Pharmaceuticals is poised for success in the biopharmaceutical industry due to its diversified pipeline and potential blockbuster status. With a highly anticipated PDUFA date for their drug mitapivat on November 1, 2021, and the potential for a broad label in sickle cell disease, there is potential for significant growth. Additionally, the company's strong platform and strategic approach to the market, along with its established hematologist prescriber base, further support its success. However, risks to achieving the price target include safety and efficacy concerns, commercial competition, regulatory decisions, financial concerns, and intellectual property protection. The recent data from comp Novo Nordisk (NVO, NR) for their PK activator etavopivat could bring potential differentiation perspectives, and with upcoming data presentations at the European Hematology Association meeting in June, there is potential for further value creation for Agios.

Bears say

Agios Pharmaceuticals is facing multiple risks, including the potential for its SCD and other drug candidates to not achieve expected revenue due to competition and regulatory concerns, as well as financial risks and risks related to intellectual property. These risks have led to a reduced peak revenue for SCD and a lowered PT of $52, indicating a negative outlook on the company's stock.

Agios Pharmaceuticals (AGIO) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agios Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agios Pharmaceuticals (AGIO) Forecast

Analysts have given Agios Pharmaceuticals (AGIO) a Buy based on their latest research and market trends.

According to 8 analysts, Agios Pharmaceuticals (AGIO) has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agios Pharmaceuticals (AGIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.